A commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy

Anne Gompel, H. Burger

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

The incidence of ovarian cancer is tenfold lower than that of breast cancer. The goal of the recently published meta-analysis by Beral and colleagues, using 'individual participant datasets from 52 epidemiological studies', was to provide an updated assessment of the effect of menopausal hormone therapy (MHT) on ovarian cancer risk. The relative risk generated from the cited prospective studies was significantly increased but the relative risk from the retrospective studies was not. This is quite unusual since retrospective studies usually display higher levels of relative risk. No further increase was observed with increasing duration. Moreover, a number of the studies could not be adjusted for important ovarian cancer risk factors. From the metaanalysis, it can be calculated that the absolute excess risk of 5 years of MHT for a 50-year-old UK woman is 1 in 10 000 per year, indicating a very low risk. We conclude that this meta-analysis mostly reflects the previously published data from the Million Women Study, from which the majority of this new publication is derived.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalClimacteric
Volume18
Issue number3
DOIs
Publication statusPublished - 1 Jun 2015
Externally publishedYes

Keywords

  • Absolute risk
  • Estrogen therapy
  • Estrogen-progestin combined therapy
  • Menopause
  • Ovarian cancer

Cite this

@article{5cbd0c25f1854f01956abdadd31d1350,
title = "A commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy",
abstract = "The incidence of ovarian cancer is tenfold lower than that of breast cancer. The goal of the recently published meta-analysis by Beral and colleagues, using 'individual participant datasets from 52 epidemiological studies', was to provide an updated assessment of the effect of menopausal hormone therapy (MHT) on ovarian cancer risk. The relative risk generated from the cited prospective studies was significantly increased but the relative risk from the retrospective studies was not. This is quite unusual since retrospective studies usually display higher levels of relative risk. No further increase was observed with increasing duration. Moreover, a number of the studies could not be adjusted for important ovarian cancer risk factors. From the metaanalysis, it can be calculated that the absolute excess risk of 5 years of MHT for a 50-year-old UK woman is 1 in 10 000 per year, indicating a very low risk. We conclude that this meta-analysis mostly reflects the previously published data from the Million Women Study, from which the majority of this new publication is derived.",
keywords = "Absolute risk, Estrogen therapy, Estrogen-progestin combined therapy, Menopause, Ovarian cancer",
author = "Anne Gompel and H. Burger",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/13697137.2015.1023615",
language = "English",
volume = "18",
pages = "376--378",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Taylor & Francis",
number = "3",

}

A commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy. / Gompel, Anne; Burger, H.

In: Climacteric, Vol. 18, No. 3, 01.06.2015, p. 376-378.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - A commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy

AU - Gompel, Anne

AU - Burger, H.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The incidence of ovarian cancer is tenfold lower than that of breast cancer. The goal of the recently published meta-analysis by Beral and colleagues, using 'individual participant datasets from 52 epidemiological studies', was to provide an updated assessment of the effect of menopausal hormone therapy (MHT) on ovarian cancer risk. The relative risk generated from the cited prospective studies was significantly increased but the relative risk from the retrospective studies was not. This is quite unusual since retrospective studies usually display higher levels of relative risk. No further increase was observed with increasing duration. Moreover, a number of the studies could not be adjusted for important ovarian cancer risk factors. From the metaanalysis, it can be calculated that the absolute excess risk of 5 years of MHT for a 50-year-old UK woman is 1 in 10 000 per year, indicating a very low risk. We conclude that this meta-analysis mostly reflects the previously published data from the Million Women Study, from which the majority of this new publication is derived.

AB - The incidence of ovarian cancer is tenfold lower than that of breast cancer. The goal of the recently published meta-analysis by Beral and colleagues, using 'individual participant datasets from 52 epidemiological studies', was to provide an updated assessment of the effect of menopausal hormone therapy (MHT) on ovarian cancer risk. The relative risk generated from the cited prospective studies was significantly increased but the relative risk from the retrospective studies was not. This is quite unusual since retrospective studies usually display higher levels of relative risk. No further increase was observed with increasing duration. Moreover, a number of the studies could not be adjusted for important ovarian cancer risk factors. From the metaanalysis, it can be calculated that the absolute excess risk of 5 years of MHT for a 50-year-old UK woman is 1 in 10 000 per year, indicating a very low risk. We conclude that this meta-analysis mostly reflects the previously published data from the Million Women Study, from which the majority of this new publication is derived.

KW - Absolute risk

KW - Estrogen therapy

KW - Estrogen-progestin combined therapy

KW - Menopause

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84929317332&partnerID=8YFLogxK

U2 - 10.3109/13697137.2015.1023615

DO - 10.3109/13697137.2015.1023615

M3 - Comment / Debate

VL - 18

SP - 376

EP - 378

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 3

ER -